Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Oncotarget. 2012 Feb;3(2):118-31.

    Targeting Mnks for cancer therapy.

    Source

    School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

    Abstract

    Deregulation of protein synthesis is a common event in human cancer and a key player in translational control is eIF4E. Elevated expression levels of eIF4E promote cancer development and progression. Recent findings suggest that eIF4E activity is a key determinant of the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK mediated tumorigenic activity and targeting eIF4E should have a major impact on these pathways in human cancer. The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK. While the phosphorylation event is necessary for oncogenic transformation, it seems to be dispensable for normal development. Hence, pharmacologic Mnk inhibitors may provide non-toxic and effective anti-cancer strategy. Strong circumstantial evidence indicates that Mnk inhibition presents attractive therapeutic potential, but the lack of selective Mnk inhibitors has so far confounded pharmacological target validation and clinical development.

    PMID:
    22392765
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3326643
    Free PMC Article

    Images from this publication.See all images (7)Free text

    Figure 2
    Figure 4
    Figure 6
    Figure 1
    Figure 3
    Figure 5
    Figure 7

      Supplemental Content

      Icon for Impact Journals, LLC Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk